A Phase IV, Open-Label, Multi-center Study to Evaluate the Safety of Apixaban in Indian Subjects Undergoing Elective Total Knee Replacement or Total Hip Replacement Surgery
Phase of Trial: Phase IV
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Apixaban (Primary) ; Enoxaparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 07 Oct 2016 Planned End Date changed from 1 Nov 2016 to 1 Feb 2018.
- 07 Oct 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Feb 2018.
- 05 Oct 2015 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov record.